Medicines Differentiation Analysis Multiple Sclerosis 18 January 2011 Mary Perkins Expected Launch Date: 3/31/2013

© Medicines Differentiation Analytics 2010 As a Patient, As a PATIENT, MS is a debilitating disease. The treatments available are only to slow down the progression. When will there be a cure or at least a treatment that significantly slows MS progression? The only oral solution has major side effects. Most of the time, I don’t take the treatments prescribed but hope that diet and exercise will help. The treatments (IV, intramuscularly or subcutaneously) are uncomfortable As a Payer, "We need a more cost effective solution without the side effects." As a PAYER, MS is a very expensive disease effecting many of our patients. The recently approved oral solution by Novartis costs $4000 a month and has significant side effects. As a Provider, As a PROVIDER, my MS patients have very little treatment options. MS is very debilitating – " a cure or more effective solution is needed for my many patients.” Often my patients don’t take my prescriptions due to the significant side effects. Multiple sclerosis Unmet Needs - Customer Value Statements As a Approver, As a REGULATOR, we recently approved an MS oral treatment because it is generally effective in slowing MS progression, but comes with significant risks. A treatment just as effective without the side effects would be approved quickly As a Caregiver,

© Medicines Differentiation Analytics 2010 Multiple sclerosis Competitive Positioning In-Line 3 1.NovartisFingold Gilenya 2.BiogenAvonex 3.Merck SeronaRebiff 4.TevaCopaxone 5.BiogenTysabri 1.BiogenBG-12 2.TevaLaquinimod 3.Genzyme-SanofiLemtrada Inline Pipeline-Phase 3 Pipeline-Phase Company/DrugStageRigor Score Company/DrugStageRigor Score Pipe-Line

© Medicines Differentiation Analytics Multiple Sclerosis Healthcare Differentiation Instrument Target Perf. Observed SOC Competitors KEY Reduction in Relapse Rate SOC reduction in Progression of Disability rate SOC Adverse Events SOCSOC Severe& Often 12 Mild&Infr eq Ability to Stay on Treatment SOCSOC Freq Disc. 12 Cont. treat Tolerability Safety Efficacy

© Medicines Differentiation Analytics Multiple Sclerosis Healthcare Differentiation Instrument Target Perf. Observed SOC Competitors KEY Administration SOCSOC Daily IV1Wkly IV Oral (1/Day) 3 2 Oral(2+d ay) Annual Cost SOC Cost Convenien ce

© Medicines Differentiation Analytics Multiple Sclerosis Real Analysis Is the Market & Opportunity REAL? Is the asset real? Are we addressing a truly unmet medical need? Is there strong justification for moving forward? Real Questions 1) Will Pateints take Multiple Sclerosis over other alternatives? ) Will Multiple Sclerosis gain Access over other alternatives? ) Will Multiple Sclerosis be Prescribed over other alternatives? ) Will Multiple Sclerosis gain Approval over other alternatives? ) Will Caregivers give Multiple Sclerosis over other alternatives? Value Sys Value Sys Rigor Real Scores

© Medicines Differentiation Analytics Multiple Sclerosis Win Analysis How capable are we internally to execute & win, timely? How competitive is the marketplace? How differentiated will we be in the market? Win Questions Sys Value Sys Rigor 11 Win Scores 1) Are we differentiated on Efficacy? ) Are we differentiated on Safety? ) Are we differentiated on Tolerability? ) Are we differentiated on Convenience? ) Are we differentiated on Cost? ) Is this Disease Area on of our internal areas of strength? Or is it a brand new area that will require new resources and capabilities (marketing, sales & manufacturing)? 11 7) Do we have the cycle times in drug development and product launches to be able to get to the market timely to win? 11 8) How likely are we to become 1st in Class or Best in Class or SOC? 11 9) Do we understand and can execute the full health care solution required (diagnostics, devices, education materials, other)? 11 10) Do our trials align with the required patient populations? 11 11) How likely is the possibility of Comparator Effectiveness Research (CER) (in new health care bill & in Europe)? 11 12) Are we prepared to mitigate CER risks? 11 13) How competitive is this Disease Area? What is the likelihood we can out perform the competition? 11 14) Can we engage with the right key opinion leaders to support our opinion? 11 15) Can we engage with the Payer community to support our opinion? 11 Value

© Medicines Differentiation Analytics Multiple Sclerosis Worth Analysis Is the opportunity WORTH the required investment? Can we make it worth it? Where can we make it worth it? Is this the right investment? Is the right strategic fit? Worth Questions 1) How large will our market share be? 2) How attractive is the Net Present Value of this asset? 3) How much development budget remains? 4) How quickly will we get reimbursed? 5) What is the life cycle potential for this drug (new indications, new markets, etc)? Worth Scores 6) Is there a strategic fit beyond financials (reputation, etc)? Value Rigor 1 1

© Medicines Differentiation Analytics 2010 Multiple Sclerosis Real, Win, Worth Summary Is the Market & Opportunity REAL? What is the unmet medical need? What is the likelihood that Stakeholders will: Take, Prescribe, Approve, & Pay For. What are the hurdles that must be overcome for stakeholders to actually take action? 9 Can we WIN? Is our Asset Differentiated, safe and effective to meet the Customer Need? Can we leverage our differentiated position? How strong is our competitive position? Are our internal capabilities well aligned with asset? Is the Opportunity WORTH the investment? Are the Sales & Profit attractive? How high is the Cost of entry? Pharm Sci, Sales force, etc. Is there Strategic Fit? Reputation, Tie to Strategy, etc. Can we leverage multiple indications? Value ScoreRigor Score Average

© Medicines Differentiation Analytics 2010 Understand needs and desired outcomes of this Asset/Project Finalize competitive landscape & parameters Build differentiation instrument & competitive label position statements Prepare Differentiated Commercialization Package Next Steps